Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders
- Autores
- Navarro, Daniela; Gasparyan, Ani; Navarrete, Francisco; Torregrosa, Abraham B.; Rubio, Gabriel; Marín Mayor, Marta; Acosta, Gabriela Beatriz; Garcia Gutiérrez, Maria Salud; Manzanares, Jorge
- Año de publicación
- 2022
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- The therapeutic benefits of the current medications for patients with psychiatric disorders contrast with a great variety of adverse effects. The endocannabinoid system (ECS) components have gained high interest as potential new targets for treating psychiatry diseases because of their neuromodulator role, which is essential to understanding the regulation of many brain functions. This article reviewed the molecular alterations in ECS occurring in different psychiatric conditions. The methods used to identify alterations in the ECS were also described. We used a translational approach. The animal models reproducing some behavioral and/or neurochemical aspects of psychiatric disorders and the molecular alterations in clinical studies in post-mortem brain tissue or peripheral tissues were analyzed. This article reviewed the most relevant ECS changes in prevalent psychiatric diseases such as mood disorders, schizophrenia, autism, attentional deficit, eating disorders (ED), and addiction. The review concludes that clinical research studies are urgently needed for two different purposes: (1) To identify alterations of the ECS components potentially useful as new biomarkers relating to a specific disease or condition, and (2) to design new therapeutic targets based on the specific alterations found to improve the pharmacological treatment in psychiatry.
Fil: Navarro, Daniela. Universidad Miguel Hernandez del Elche; España
Fil: Gasparyan, Ani. Universidad Miguel Hernandez del Elche; España
Fil: Navarrete, Francisco. Universidad Miguel Hernandez del Elche; España
Fil: Torregrosa, Abraham B.. Universidad Miguel Hernandez del Elche; España
Fil: Rubio, Gabriel. Hospital Universitario 12 de Octubre; España
Fil: Marín Mayor, Marta. Hospital Universitario 12 de Octubre; España
Fil: Acosta, Gabriela Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Neurociencia Cognitiva. Fundación Favaloro. Instituto de Neurociencia Cognitiva; Argentina
Fil: Garcia Gutiérrez, Maria Salud. Universidad Miguel Hernandez del Elche; España
Fil: Manzanares, Jorge. Universidad Miguel Hernandez del Elche; España - Materia
-
ENDOCANNABINOID SYSTEM
METHOD
MOLECULAR ALTERATION
PSYCHIATRIC DISORDERS - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/211453
Ver los metadatos del registro completo
id |
CONICETDig_139eeb994da24908debef3577f7d037c |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/211453 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Molecular Alterations of the Endocannabinoid System in Psychiatric DisordersNavarro, DanielaGasparyan, AniNavarrete, FranciscoTorregrosa, Abraham B.Rubio, GabrielMarín Mayor, MartaAcosta, Gabriela BeatrizGarcia Gutiérrez, Maria SaludManzanares, JorgeENDOCANNABINOID SYSTEMMETHODMOLECULAR ALTERATIONPSYCHIATRIC DISORDERShttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3The therapeutic benefits of the current medications for patients with psychiatric disorders contrast with a great variety of adverse effects. The endocannabinoid system (ECS) components have gained high interest as potential new targets for treating psychiatry diseases because of their neuromodulator role, which is essential to understanding the regulation of many brain functions. This article reviewed the molecular alterations in ECS occurring in different psychiatric conditions. The methods used to identify alterations in the ECS were also described. We used a translational approach. The animal models reproducing some behavioral and/or neurochemical aspects of psychiatric disorders and the molecular alterations in clinical studies in post-mortem brain tissue or peripheral tissues were analyzed. This article reviewed the most relevant ECS changes in prevalent psychiatric diseases such as mood disorders, schizophrenia, autism, attentional deficit, eating disorders (ED), and addiction. The review concludes that clinical research studies are urgently needed for two different purposes: (1) To identify alterations of the ECS components potentially useful as new biomarkers relating to a specific disease or condition, and (2) to design new therapeutic targets based on the specific alterations found to improve the pharmacological treatment in psychiatry.Fil: Navarro, Daniela. Universidad Miguel Hernandez del Elche; EspañaFil: Gasparyan, Ani. Universidad Miguel Hernandez del Elche; EspañaFil: Navarrete, Francisco. Universidad Miguel Hernandez del Elche; EspañaFil: Torregrosa, Abraham B.. Universidad Miguel Hernandez del Elche; EspañaFil: Rubio, Gabriel. Hospital Universitario 12 de Octubre; EspañaFil: Marín Mayor, Marta. Hospital Universitario 12 de Octubre; EspañaFil: Acosta, Gabriela Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Neurociencia Cognitiva. Fundación Favaloro. Instituto de Neurociencia Cognitiva; ArgentinaFil: Garcia Gutiérrez, Maria Salud. Universidad Miguel Hernandez del Elche; EspañaFil: Manzanares, Jorge. Universidad Miguel Hernandez del Elche; EspañaMolecular Diversity Preservation International2022-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/211453Navarro, Daniela; Gasparyan, Ani; Navarrete, Francisco; Torregrosa, Abraham B.; Rubio, Gabriel; et al.; Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders; Molecular Diversity Preservation International; International Journal of Molecular Sciences; 23; 9; 4-2022; 1-661422-0067CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/1422-0067/23/9/4764info:eu-repo/semantics/altIdentifier/doi/10.3390/ijms23094764info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:50:58Zoai:ri.conicet.gov.ar:11336/211453instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:50:58.953CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders |
title |
Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders |
spellingShingle |
Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders Navarro, Daniela ENDOCANNABINOID SYSTEM METHOD MOLECULAR ALTERATION PSYCHIATRIC DISORDERS |
title_short |
Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders |
title_full |
Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders |
title_fullStr |
Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders |
title_full_unstemmed |
Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders |
title_sort |
Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders |
dc.creator.none.fl_str_mv |
Navarro, Daniela Gasparyan, Ani Navarrete, Francisco Torregrosa, Abraham B. Rubio, Gabriel Marín Mayor, Marta Acosta, Gabriela Beatriz Garcia Gutiérrez, Maria Salud Manzanares, Jorge |
author |
Navarro, Daniela |
author_facet |
Navarro, Daniela Gasparyan, Ani Navarrete, Francisco Torregrosa, Abraham B. Rubio, Gabriel Marín Mayor, Marta Acosta, Gabriela Beatriz Garcia Gutiérrez, Maria Salud Manzanares, Jorge |
author_role |
author |
author2 |
Gasparyan, Ani Navarrete, Francisco Torregrosa, Abraham B. Rubio, Gabriel Marín Mayor, Marta Acosta, Gabriela Beatriz Garcia Gutiérrez, Maria Salud Manzanares, Jorge |
author2_role |
author author author author author author author author |
dc.subject.none.fl_str_mv |
ENDOCANNABINOID SYSTEM METHOD MOLECULAR ALTERATION PSYCHIATRIC DISORDERS |
topic |
ENDOCANNABINOID SYSTEM METHOD MOLECULAR ALTERATION PSYCHIATRIC DISORDERS |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.3 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
The therapeutic benefits of the current medications for patients with psychiatric disorders contrast with a great variety of adverse effects. The endocannabinoid system (ECS) components have gained high interest as potential new targets for treating psychiatry diseases because of their neuromodulator role, which is essential to understanding the regulation of many brain functions. This article reviewed the molecular alterations in ECS occurring in different psychiatric conditions. The methods used to identify alterations in the ECS were also described. We used a translational approach. The animal models reproducing some behavioral and/or neurochemical aspects of psychiatric disorders and the molecular alterations in clinical studies in post-mortem brain tissue or peripheral tissues were analyzed. This article reviewed the most relevant ECS changes in prevalent psychiatric diseases such as mood disorders, schizophrenia, autism, attentional deficit, eating disorders (ED), and addiction. The review concludes that clinical research studies are urgently needed for two different purposes: (1) To identify alterations of the ECS components potentially useful as new biomarkers relating to a specific disease or condition, and (2) to design new therapeutic targets based on the specific alterations found to improve the pharmacological treatment in psychiatry. Fil: Navarro, Daniela. Universidad Miguel Hernandez del Elche; España Fil: Gasparyan, Ani. Universidad Miguel Hernandez del Elche; España Fil: Navarrete, Francisco. Universidad Miguel Hernandez del Elche; España Fil: Torregrosa, Abraham B.. Universidad Miguel Hernandez del Elche; España Fil: Rubio, Gabriel. Hospital Universitario 12 de Octubre; España Fil: Marín Mayor, Marta. Hospital Universitario 12 de Octubre; España Fil: Acosta, Gabriela Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Neurociencia Cognitiva. Fundación Favaloro. Instituto de Neurociencia Cognitiva; Argentina Fil: Garcia Gutiérrez, Maria Salud. Universidad Miguel Hernandez del Elche; España Fil: Manzanares, Jorge. Universidad Miguel Hernandez del Elche; España |
description |
The therapeutic benefits of the current medications for patients with psychiatric disorders contrast with a great variety of adverse effects. The endocannabinoid system (ECS) components have gained high interest as potential new targets for treating psychiatry diseases because of their neuromodulator role, which is essential to understanding the regulation of many brain functions. This article reviewed the molecular alterations in ECS occurring in different psychiatric conditions. The methods used to identify alterations in the ECS were also described. We used a translational approach. The animal models reproducing some behavioral and/or neurochemical aspects of psychiatric disorders and the molecular alterations in clinical studies in post-mortem brain tissue or peripheral tissues were analyzed. This article reviewed the most relevant ECS changes in prevalent psychiatric diseases such as mood disorders, schizophrenia, autism, attentional deficit, eating disorders (ED), and addiction. The review concludes that clinical research studies are urgently needed for two different purposes: (1) To identify alterations of the ECS components potentially useful as new biomarkers relating to a specific disease or condition, and (2) to design new therapeutic targets based on the specific alterations found to improve the pharmacological treatment in psychiatry. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-04 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/211453 Navarro, Daniela; Gasparyan, Ani; Navarrete, Francisco; Torregrosa, Abraham B.; Rubio, Gabriel; et al.; Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders; Molecular Diversity Preservation International; International Journal of Molecular Sciences; 23; 9; 4-2022; 1-66 1422-0067 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/211453 |
identifier_str_mv |
Navarro, Daniela; Gasparyan, Ani; Navarrete, Francisco; Torregrosa, Abraham B.; Rubio, Gabriel; et al.; Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders; Molecular Diversity Preservation International; International Journal of Molecular Sciences; 23; 9; 4-2022; 1-66 1422-0067 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/1422-0067/23/9/4764 info:eu-repo/semantics/altIdentifier/doi/10.3390/ijms23094764 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Molecular Diversity Preservation International |
publisher.none.fl_str_mv |
Molecular Diversity Preservation International |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1842269064982953984 |
score |
13.13397 |